Back to School: How biopharma can reboot drug development. Access exclusive analysis here
EVT will acquire RNVS for $4.75 per share, or about $151.8 million in stock. The price is a 43% premium to RNVS's close of $3.32 on Sept.
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury